Drugs / EXN407
last change Nov 2022 re-read 3 minutes ago

EXN407

Developed for
diabetic macular edema
Investigated by
Exonate Limited · Novotech (Australia) Pty Limited

Trials 1

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04565756 Nov 2020 → Oct 2022 diabetic macular edema Exonate Limited Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as EXN407 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04565756 ↗